{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-induced+Nausea+and+Vomiting+%28CINV%29", "query": { "condition": "Chemotherapy-induced Nausea and Vomiting (CINV)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemotherapy-induced+Nausea+and+Vomiting+%28CINV%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-12T08:47:58.362Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00880191", "title": "Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "gabapentin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2009-04", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 247, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 163 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00880191" }, { "nct_id": "NCT01596400", "title": "Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chemotherapy Induced Nausea and Vomiting" ], "interventions": [ { "name": "granisetron transdermal system", "type": "DRUG" }, { "name": "Granisetron IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Pharmaceutical Development Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 19, "start_date": "2012-05", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2024-06-17", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 12, "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596400" }, { "nct_id": "NCT04085393", "title": "Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "GRANISETRON EXTENDED RELEASE INJECTION (GERSC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-08-15", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2020-09-30", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04085393" }, { "nct_id": "NCT05319860", "title": "Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)", "type": "DRUG" }, { "name": "Aromatherapy Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-08-01", "completion_date": "2024-04-15", "has_results": true, "last_update_posted_date": "2025-04-17", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319860" }, { "nct_id": "NCT03578081", "title": "Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Palonosetron Hydrochloride", "type": "DRUG" }, { "name": "Ondansetron Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fosaprepitant Dimeglumine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 690, "start_date": "2018-11-20", "completion_date": "2023-05-01", "has_results": true, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 565, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03578081" }, { "nct_id": "NCT05199818", "title": "Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Palonosetron HCl Buccal Film 0.5 mg", "type": "DRUG" }, { "name": "IV Palonosetron 0.25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xiamen LP Pharmaceutical Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2022-03-01", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2023-01-20", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 13, "location_summary": "Chandler, Arizona • Anaheim, California • Lakeland, Florida + 9 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199818" }, { "nct_id": "NCT07169851", "title": "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nausea", "Vomiting", "Drug-Related Side Effects and Adverse Reactions", "Neoplasms" ], "interventions": [ { "name": "LY3537021", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care Antiemetic Therapies", "type": "DRUG" }, { "name": "Background Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2025-11-28", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 20, "location_summary": "Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169851" }, { "nct_id": "NCT04535141", "title": "Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Olanzapine 5 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2020-08-18", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04535141" }, { "nct_id": "NCT04054193", "title": "Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Fosaprepitant Dimeglumine", "type": "DRUG" }, { "name": "5-HT3 antagonist", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 103, "start_date": "2019-09-09", "completion_date": "2021-02-11", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04054193" }, { "nct_id": "NCT02635984", "title": "Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complications of Bone Marrow Transplant", "Hematologic Neoplasms" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2015-11", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-10-12T08:47:58.362Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635984" } ] }